Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study.
| Title: | Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study. |
|---|---|
| Authors: | Vencio S; UFG - Federal University of Goiás, Goiânia, GO, Brazil. svencio@gmail.com.; ICF, Pharmaceutical Institute of Science, Av. Rio Verde, S/N - Cidade Vera Cruz, Aparecida de Goiânia, GO, 74935-530, Brazil. svencio@gmail.com.; Vianna AGD; Curitiba Diabetes Center, Curitiba, PR, Brazil.; Nossa Senhora das Graças Hospital, Curitiba, PR, Brazil.; da Silva MACF; Novo Nordisk, São Paulo, SP, Brazil.; Precoma DB; Research Center at Angelina Caron Hospital, Campina Grande do Sul, PR, Brazil. |
| Source: | Diabetology & metabolic syndrome [Diabetol Metab Syndr] 2022 Jan 10; Vol. 14 (1), pp. 5. Date of Electronic Publication: 2022 Jan 10. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101488958 Publication Model: Electronic Cited Medium: Print ISSN: 1758-5996 (Print) Linking ISSN: 17585996 NLM ISO Abbreviation: Diabetol Metab Syndr Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: [London] : BioMed Central |
| Abstract: | Background: Type 2 diabetes (T2D) is a known risk factor for cardiovascular disease (CVD), and CVD is a major cause of mortality in patients with T2D. The CAPTURE study investigated the contemporary (2019) prevalence of established CVD in adults with T2D around the world. We report the findings from Brazil.; Methods: The multinational, non-interventional, cross-sectional CAPTURE study was conducted across 13 countries from five continents. The current manuscript explores data for the CAPTURE study sample in Brazil. Standardized demographic and clinical data were collected from adults with T2D aged ≥ 18 years attending a single routine healthcare visit in primary or specialized care between December 2018 and September 2019. Data were analyzed descriptively.; Results: Data from 912 adults with T2D were collected in the CAPTURE study in Brazil, with 822 patients from primary care and 90 patients from specialized care. Median (interquartile range [IQR]) patient characteristics were as follows: age 64 years (57; 71), diabetes duration 11 years (6; 19), glycated hemoglobin 7.7% (6.7; 9.1), and body mass index 29.5 kg/m2 (26.4; 33.5); 59% were female. The CVD prevalence and atherosclerotic CVD prevalence in the Brazil sample were 43.9% (95% confidence interval [CI] 40.9; 46.8) and 37.6% (95% CI 34.7; 40.5), respectively. The majority of patients with CVD had atherosclerotic CVD (85.8%). For the specific CVD subtypes, coronary heart disease prevalence was 27.9% (95% CI 25.2; 30.5), heart failure was 12.4% (95% CI 10.4; 14.4), cerebrovascular disease was 8.7% (95% CI 6.8; 10.5), and carotid artery disease was 3.4% (95% CI 2.3; 4.5). Glucagon-like peptide-1 receptor agonists and/or sodium-glucose co-transporter-2 inhibitors with proven cardiovascular benefit were prescribed to 15.5% of patients with CVD, compared with 18.4% of patients without CVD.; Conclusions: CAPTURE was the first multinational, standardized study to provide contemporary data on CVD prevalence in adults with T2D in Brazil, and it demonstrated that almost one in two adults with T2D had established CVD. Except for carotid artery disease, the prevalence of all CVD subtypes in adults with T2D in Brazil appeared higher than the global CAPTURE prevalence. Trial registration NCT03786406, NCT03811288.; (© 2022. The Author(s).) |
| References: | Diabetol Metab Syndr. 2014 Nov 18;6:123. (PMID: 25788987); N Engl J Med. 2019 Jan 24;380(4):347-357. (PMID: 30415602); Diabetes Care. 1992 Nov;15(11):1509-16. (PMID: 1468278); J Diabetes Complications. 2021 Mar;35(3):107813. (PMID: 33419634); JAMA. 2013 Nov 27;310(20):2191-4. (PMID: 24141714); Cardiovasc Diabetol. 2021 Jul 27;20(1):154. (PMID: 34315481); Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1217-1224. (PMID: 32682310); Circulation. 2018 Jan 23;137(4):323-334. (PMID: 29133604); N Engl J Med. 2016 Nov 10;375(19):1834-1844. (PMID: 27633186); Diabetol Metab Syndr. 2009 Oct 27;1(1):22. (PMID: 19860912); Diabetes Metab Syndr Obes. 2015 Jan 05;8:17-28. (PMID: 25609989); N Engl J Med. 2015 Nov 26;373(22):2117-28. (PMID: 26378978); Cardiovasc Diabetol. 2018 Jun 8;17(1):83. (PMID: 29884191); Lancet. 2019 Jul 13;394(10193):121-130. (PMID: 31189511); Diabetol Metab Syndr. 2017 Jul 14;9:53. (PMID: 28725272); Diabetol Metab Syndr. 2017 Jun 15;9:46. (PMID: 28638444); N Engl J Med. 2016 Jul 28;375(4):311-22. (PMID: 27295427); Diabetes Care. 2017 Jul;40(7):813-820. (PMID: 28637886); World J Diabetes. 2014 Aug 15;5(4):444-70. (PMID: 25126392); Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124. (PMID: 33298420); Diabetes Care. 2020 Jan;43(Suppl 1):S111-S134. (PMID: 31862753); J Am Coll Cardiol. 2019 Sep 10;74(10):1376-1414. (PMID: 30894319) |
| Contributed Indexing: | Keywords: Atherosclerosis; Brazil; Cardiovascular disease; Cross-sectional study; Prevalence; Type 2 diabetes |
| Molecular Sequence: | ClinicalTrials.gov NCT03786406; NCT03811288 |
| Entry Date(s): | Date Created: 20220111 Latest Revision: 20220114 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC8751351 |
| DOI: | 10.1186/s13098-021-00775-9 |
| PMID: | 35012646 |
| Database: | MEDLINE |
Journal Article